By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Sosei Co., Ltd. 

4F, Kojimachi NK Building
2-14-2 Kojimachi, Chiyoda-ku
Tokyo    102-0083  Japan
Phone: 81-3-5210-3290 Fax: 81-3-5210-3291



Start Up

Company News
Sosei Release: Company Appoints Andrew Oakley As CFO 1/19/2017 8:51:25 AM
Sosei Subsidiaries Heptares And Jitsubo To Develop Novel GPCR-Targeting Peptide Candidates For Severe Gastro-Intestinal Disorders 11/10/2016 2:34:42 PM
Sosei Names a New CEO, Effective Immediately 6/24/2016 6:07:23 AM
Sosei Appoints Peter Bains As COO And CEO-Elect 3/22/2016 10:21:07 AM
Sosei Subsidiary Heptares Announces Positive Results From Phase 1b Clinical Trial With HTL9936, A First-In-Class Selective Muscarinic M1Receptor Agonist For Improving Cognition In Dementia And Schizophrenia 2/10/2016 10:51:21 AM
Pfizer (PFE) Inks $1.89 Billion Discovery Deal with Heptares, Takes $33 Million Stake in Sosei 11/30/2015 5:57:26 AM
Sosei Subsidiary Heptares Announces Positive Outcome Of Phase 1a Study With First-Ever Selective Muscarinic M1 Receptor Agonist For Improving Cognition In Patients With Alzheimer's Disease 6/17/2015 11:16:21 AM
Sosei Snags UK Biotech Firm Heptares for $400 Million 2/23/2015 5:54:15 AM
BioAlliance Pharma Pursues the Development Plan of Its Loramyc® in Japan Through Its Partner Sosei 3/12/2013 12:05:50 PM
BioAlliance Pharma: Progress in the Development of Loramyc(R) in Japan Towards its Registration by the Partner Sosei Co., Ltd. 7/2/2012 12:31:19 PM